US · SLP · SOFTWARE - APPLICATION
Simulations Plus, Inc. (SLP) intrinsic value and stock valuation
$18.50as of 2026-11-21 · Mkt cap 370.52M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Simulations Plus, Inc. DCF and intrinsic value
InvestorsCraft values SLP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SLP’s statements →
Simulations Plus, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Agilon Health, Inc. (AGL) $90.24
- Alto Neuroscience, Inc. (ANRO) $25.37
- NRC Health (NRC) $25.16
- SOPHiA GENETICS S.A. (SOPH) $6.23
- Cellectis S.A. (CLLS) $0.92
- AC Immune S.A. (ACIU) $1.95
- OptimizeRx Corp. (OPRX) $6.70
- Korro Bio, Inc. (KRRO) $12.18
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $79.2M | $70M | $59.6M | $53.9M | $46.5M |
| Operating income | -$-70.73M | $6.13M | $8.72M | $14.9M | $11.3M |
| Net income | -$-64.72M | $9.95M | $9.96M | $12.5M | $9.78M |
| EPSd | -$-3.22M | $490.1K | $486.8K | $601.4K | $471.6K |
| Operating cash flow | $18.1M | $13.3M | $21.9M | $17.9M | $19.2M |
| Capital expenditure | -$-710K | -$-570K | -$-4.27M | -$-3.97M | -$-4.58M |
| Free cash flow | $17.4M | $12.8M | $17.6M | $13.9M | $14.6M |
| Total assets | $131.9M | $207.6M | $192.6M | $190.5M | $181.6M |
| Total debt | $620K | $1.01M | $1.2M | $1.4M | $1.28M |
| Net debt | -$-30.24M | -$-9.3M | -$-56.33M | -$-50.16M | -$-35.71M |
| Total equity | $124.8M | $182.4M | $170M | $178.3M | $165.8M |
| Cash and short-term investments | $32.4M | $20.3M | $115.5M | $128.2M | $123.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $79.2M | $70M | $59.6M | $53.9M | $46.5M |
| Cost of revenue | $33M | $26.9M | $11.6M | $10.8M | $10.6M |
| Gross profit | $46.2M | $43.2M | $48M | $43.1M | $35.9M |
| Research and development expenses | $6.88M | $5.75M | $4.5M | $3.21M | $4.05M |
| Selling, general and administrative expenses | $32.8M | $31.3M | $34.7M | $25M | $20.6M |
| Other expenses | $77.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $117M | $37M | $39.2M | $28.2M | $24.6M |
| Cost and expenses | $149.9M | $63.9M | $50.9M | $39M | $35.2M |
| Interest income | $720K | $4.38M | $4.13M | $720K | $200K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $20K |
| Depreciation and amortization | $8.21M | $5.67M | $3.84M | $3.57M | $3.59M |
| Ebitda | $14.7M | $18.1M | $13.1M | $18.7M | $14.7M |
| Operating income | -$-70.73M | $6.13M | $8.72M | $14.9M | $11.3M |
| Total other income/expenses, net | $1.35M | $6.28M | $2.97M | $200K | -$-170K |
| Income before tax | -$-69.38M | $12.4M | $11.7M | $15.1M | $11.1M |
| Income tax expense | -$-4.66M | $2.46M | $1.73M | $2.63M | $1.3M |
| Net income | -$-64.72M | $9.95M | $9.96M | $12.5M | $9.78M |
| Weighted average shares outstanding | $20.1M | $20M | $20.1M | $20.2M | $20.1M |
| Weighted average diluted shares outstanding | $20.1M | $20.3M | $20.5M | $20.8M | $20.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $32.4M | $20.3M | $115.5M | $128.2M | $123.6M |
| Net receivables | $14.6M | $9.14M | $10.2M | $13.8M | $13.1M |
| Inventory | $0.00 | $0.00 | $800K | $1.39M | $1.01M |
| Total current assets | $51.6M | $39.3M | $130.4M | $146.8M | $139.3M |
| Property, plant and equipment, net | $1.29M | $1.84M | $1.92M | $2.05M | $3.11M |
| Goodwill and intangible assets | $72.9M | $154.9M | $52M | $39.1M | $37.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $80.4M | $168.3M | $62.3M | $43.7M | $42.3M |
| Total assets | $131.9M | $207.6M | $192.6M | $190.5M | $181.6M |
| Accounts payable | $470K | $600K | $140K | $230K | $390K |
| Short-term debt | $210K | $470K | $440K | $460K | $380K |
| Deferred revenue | $2.7M | $2M | $3.1M | $2.86M | $650K |
| Total current liabilities | $6.72M | $12.1M | $12M | $7.74M | $11.6M |
| Long-term debt | $410K | $530K | $760K | $940K | $900K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $410K | $13.1M | $10.6M | $4.52M | $4.26M |
| Capital lease obligations | $410K | $530K | $760K | $940K | $1.28M |
| Total liabilities | $7.13M | $25.2M | $22.6M | $12.3M | $15.8M |
| Common stock | $20K | $20K | $145M | $138.5M | $133.4M |
| Retained earnings | -$-34.36M | $30.4M | $25.2M | $40M | $32.4M |
| Accumulated other comprehensive income (loss) | -$-270K | -$-250K | -$-140K | -$-310K | -$-40K |
| Total equity | $124.8M | $182.4M | $170M | $178.3M | $165.8M |
| Total investments | $1.5M | $9.94M | $57.9M | $76.7M | $86.6M |
| Total debt | $620K | $1.01M | $1.2M | $1.4M | $1.28M |
| Net debt | -$-30.24M | -$-9.3M | -$-56.33M | -$-50.16M | -$-35.71M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-64.72M | $9.95M | $9.96M | $12.5M | $9.78M |
| Depreciation and amortization | $8.21M | $5.67M | $3.84M | $3.57M | $3.59M |
| Stock-based compensation | $6.35M | $6.54M | $4.83M | $3.04M | $2.75M |
| Change in working capital | -$-2.59M | -$-4.21M | $5.1M | -$-2.62M | $970K |
| Accounts receivable | -$-580K | $3.13M | $4.1M | -$-3.94M | -$-2.43M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $3.15M |
| Accounts payable | -$-130K | -$-480K | -$-80K | -$-160K | $40K |
| Net cash provided by operating activities | $18.1M | $13.3M | $21.9M | $17.9M | $19.2M |
| Investments in property, plant and equipment | -$-710K | -$-570K | -$-450K | -$-3.97M | -$-4.58M |
| Acquisitions, net | $0.00 | -$-98.77M | -$-8.22M | $3.15M | $2.95M |
| Net cash used for investing activities | $3.56M | -$-53.97M | $7.37M | $4.3M | -$-26.74M |
| Common stock issued | $430K | $730K | $0.00 | $890K | $1.46M |
| Common stock repurchased | $0.00 | $0.00 | -$-20M | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-4.8M | -$-4.81M | -$-4.85M | -$-4.81M |
| Net cash used for financing activities | -$-1.15M | -$-6.57M | -$-23.27M | -$-7.62M | -$-4.68M |
| Net change in cash | $20.5M | -$-47.21M | $5.96M | $14.6M | -$-12.22M |
| Cash at end of period | $30.9M | $10.3M | $57.5M | $51.6M | $37M |
| Operating cash flow | $18.1M | $13.3M | $21.9M | $17.9M | $19.2M |
| Capital expenditure | -$-710K | -$-570K | -$-4.27M | -$-3.97M | -$-4.58M |
| Free cash flow | $17.4M | $12.8M | $17.6M | $13.9M | $14.6M |
Line items
Line items
Line items
About Simulations Plus, Inc.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
- CEO
- Shawn O'Connor
- Employees
- 213
- Beta
- 1.31
Explore
Frequently asked questions
What is the intrinsic value of Simulations Plus, Inc. (SLP)?
Simulations Plus, Inc. (SLP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SLP undervalued?
SLP trades at a price of $18.50 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.